Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

14 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Repeatability and Reproducibility of ADC Measurements and MRI Signal Intensity Measurements of Bone Marrow in Monoclonal Plasma Cell Disorders: A Prospective Bi-institutional Multiscanner, Multiprotocol Study.
Wennmann M, Thierjung H, Bauer F, Weru V, Hielscher T, Grözinger M, Gnirs R, Sauer S, Goldschmidt H, Weinhold N, Bonekamp D, Schlemmer HP, Weber TF, Delorme S, Rotkopf LT. Wennmann M, et al. Among authors: weru v. Invest Radiol. 2022 Apr 1;57(4):272-281. doi: 10.1097/RLI.0000000000000838. Invest Radiol. 2022. PMID: 34839306
Detection of Clinically Significant Prostate Cancer Using Targeted Biopsy with Four Cores Versus Target Saturation Biopsy with Nine Cores in Transperineal Prostate Fusion Biopsy: A Prospective Randomized Trial.
Saner YM, Wiesenfarth M, Weru V, Ladyzhensky B, Tschirdewahn S, Püllen L, Bonekamp D, Reis H, Krafft U, Heß J, Kesch C, Darr C, Forsting M, Wetter A, Umutlu L, Haubold J, Hadaschik B, Radtke JP. Saner YM, et al. Among authors: weru v. Eur Urol Oncol. 2023 Feb;6(1):49-55. doi: 10.1016/j.euo.2022.08.005. Epub 2022 Sep 26. Eur Urol Oncol. 2023. PMID: 36175281 Clinical Trial.
Deep Learning for Automatic Bone Marrow Apparent Diffusion Coefficient Measurements From Whole-Body Magnetic Resonance Imaging in Patients With Multiple Myeloma: A Retrospective Multicenter Study.
Wennmann M, Neher P, Stanczyk N, Kahl KC, Kächele J, Weru V, Hielscher T, Grözinger M, Chmelik J, Zhang KS, Bauer F, Nonnenmacher T, Debic M, Sauer S, Rotkopf LT, Jauch A, Schlamp K, Mai EK, Weinhold N, Afat S, Horger M, Goldschmidt H, Schlemmer HP, Weber TF, Delorme S, Kurz FT, Maier-Hein K. Wennmann M, et al. Among authors: weru v. Invest Radiol. 2023 Apr 1;58(4):273-282. doi: 10.1097/RLI.0000000000000932. Epub 2022 Oct 3. Invest Radiol. 2023. PMID: 36256790
Test-retest, inter- and intra-rater reproducibility of size measurements of focal bone marrow lesions in MRI in patients with multiple myeloma.
Wennmann M, Grözinger M, Weru V, Hielscher T, Rotkopf LT, Bauer F, Gnirs R, Nonnenmacher T, Sauer S, Goldschmidt H, Weinhold N, Bonekamp D, Weber TF, Schlemmer HP, Delorme S. Wennmann M, et al. Among authors: weru v. Br J Radiol. 2023 Apr 1;96(1145):20220745. doi: 10.1259/bjr.20220745. Epub 2023 Apr 12. Br J Radiol. 2023. PMID: 37001052 Free PMC article.
Inflammatory exposure drives long-lived impairment of hematopoietic stem cell self-renewal activity and accelerated aging.
Bogeska R, Mikecin AM, Kaschutnig P, Fawaz M, Büchler-Schäff M, Le D, Ganuza M, Vollmer A, Paffenholz SV, Asada N, Rodriguez-Correa E, Frauhammer F, Buettner F, Ball M, Knoch J, Stäble S, Walter D, Petri A, Carreño-Gonzalez MJ, Wagner V, Brors B, Haas S, Lipka DB, Essers MAG, Weru V, Holland-Letz T, Mallm JP, Rippe K, Krämer S, Schlesner M, McKinney Freeman S, Florian MC, King KY, Frenette PS, Rieger MA, Milsom MD. Bogeska R, et al. Among authors: weru v. Cell Stem Cell. 2022 Aug 4;29(8):1273-1284.e8. doi: 10.1016/j.stem.2022.06.012. Epub 2022 Jul 19. Cell Stem Cell. 2022. PMID: 35858618 Free PMC article.
The prognostic value of [18F]FDG PET/CT based response monitoring in metastatic melanoma patients undergoing immunotherapy: comparison of different metabolic criteria.
Sachpekidis C, Weru V, Kopp-Schneider A, Hassel JC, Dimitrakopoulou-Strauss A. Sachpekidis C, et al. Among authors: weru v. Eur J Nucl Med Mol Imaging. 2023 Jul;50(9):2699-2714. doi: 10.1007/s00259-023-06243-y. Epub 2023 Apr 26. Eur J Nucl Med Mol Imaging. 2023. PMID: 37099131 Free PMC article.
Low level of antioxidant capacity biomarkers but not target overexpression predicts vulnerability to ROS-inducing drugs.
Samarin J, Fabrowski P, Kurilov R, Nuskova H, Hummel-Eisenbeiss J, Pink H, Li N, Weru V, Alborzinia H, Yildiz U, Grob L, Taubert M, Czech M, Morgen M, Brandstädter C, Becker K, Mao L, Jayavelu AK, Goncalves A, Uhrig U, Seiler J, Lyu Y, Diederichs S, Klingmüller U, Muckenthaler M, Kopp-Schneider A, Teleman A, Miller AK, Gunkel N. Samarin J, et al. Among authors: weru v. Redox Biol. 2023 Jun;62:102639. doi: 10.1016/j.redox.2023.102639. Epub 2023 Feb 23. Redox Biol. 2023. PMID: 36958250 Free PMC article.
14 results